Cassava Sciences Inc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while iShares 20 Plus Year Treasury Bond ETF trades at $77.8 (market cap $47.61B). The key difference: iShares 20 Plus Year Treasury Bond ETF is far larger — about 1208.4× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 49,263,490). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and iShares 20 Plus Year Treasury Bond ETF for 83 Days on average.
| FLNA | TLT | |
|---|---|---|
Market Cap | $39.40M | $47.61B |
Volume | 759,018 | 49,263,490 |
Sector | Health | Fixed Income |
52-Week High | $4.64 | $92.06 |
52-Week Low | $0.68 | $77.11 |
Typical Hold Time | 37 Days | 83 Days |
Enterprise Value | -$43.28M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $77.145, down 0.17% amid a challenging bond market environment. The technical picture is bearish with moving averages signaling strong selling pressure, though oscillators are neutral. Recent news highlights Treasury yields reaching multi-decade highs, with the fund experiencing significant outflows and declining nearly 50% over five years as rising interest rates pressure long-duration bonds.
The outlook remains pressured by persistent high interest rates and inflation concerns. While current yields above 5% offer income appeal, further rate hikes or prolonged elevated rates could extend the downtrend. Key risks include Federal Reserve policy uncertainty and economic data volatility. Investors should weigh the income potential against continued price depreciation risk in the current macro environment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →